About Thyrocare Technologies Limited

Thyrocare Technologies Limited is a listed diagnostics company headquartered in Navi Mumbai, delivering IT-enabled, fully automated laboratory services since 1996 and incorporated on January 28, 2000. It operates a nationwide network of 29 NABL-accredited laboratories comprising 2 Central Processing Labs, 19 Regional Processing Labs, 2 Zonal Processing Labs and 6 Satellite Processing Labs, with a growing international footprint that includes a laboratory in Tanzania. Its consumer and clinician-focused portfolios span Aarogyam (preventive health), Jaanch (doctor-curated diagnostics) and Her Check (women’s wellness). The company reports industry-leading turnaround, releasing 98% of reports within six hours. Equity shares are listed on NSE and BSE. Thyrocare offers over 920 diagnostic tests delivered to homes across 4,600 pin codes and provides ECG at Home services in 1,000+ pin codes. The company has 3 subsidiaries. Key milestones in the latest year include strategic acquisitions, expansion of accredited labs and commissioning of the Tanzania lab.

Products and services include diagnostic testing services, imaging services and sale of testing equipment and consumables (including glucometers and glucostrips under the Sugarscan brand).

Thyrocare Technologies Limited Business Segments

• Pathology: 89.22% of revenue
• Radiology: 7.90%
• Materials & Others: 2.89%

Thyrocare Technologies Limited Key Management

• Rahul Guha – Chairman, Managing Director and CEO
• Alok Kumar Jagnani – Chief Financial Officer
• Brijesh Kumar – Company Secretary and Compliance Officer

Latest Updates on Thyrocare Technologies Limited

• Acquisitions: Thyrocare acquired the diagnostics business of Polo Labs Private Limited through a Business Transfer Agreement, expanding presence across Punjab, Haryana and Himachal Pradesh. It also completed the acquisition of the clinical diagnostic business of Vimta Labs Limited on October 11, 2024, strengthening operations across multiple cities in southern and eastern India.
• International expansion: Thyrocare Laboratories (Tanzania) Limited went live in March 2024, processed its first sample in April 2024 and has partnered with 100+ healthcare facilities in Dar es Salaam.
• Network and quality: NABL-accredited labs increased from 25 to 29. The company continues to maintain high standards with 100% NABL accreditation across its 29 owned labs in India, alongside long-standing CAP recognition.
• Service reach: ECG at Home now covers 1,000+ pin codes with a dedicated fleet of ECG phlebotomists; home sample collection spans over 4,600 pin codes with 920+ tests available.
• Operating scale: Around 167.9 million tests were conducted during the year, reflecting 14% year-on-year growth.
• Governance update: The company disclosed material related party transactions with its holding company, Docon Technologies Private Limited, covering diagnostic testing services and sale of consumables, with shareholder approval obtained earlier.